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Background: Cardiac hypertrophy is central to the etiology of heart failure. Understanding the molecular pathways
promoting cardiac hypertrophy may identify new targets for therapeutic intervention. Sodium-proton exchanger
(NHE1) activity and expression levels in the heart are elevated in many models of hypertrophy through protein
kinase C (PKC)/MAPK/ERK/p90RSK pathway stimulation. Sustained NHE1 activity, however, requires an acid-loading
pathway. Evidence suggests that the Cl−/HCO3
− exchanger, AE3, provides this acid load. Here we explored the role
of AE3 in the hypertrophic growth cascade of cardiomyocytes.
Methods: AE3-deficient (ae3−/−) mice were compared to wildtype (WT) littermates to examine the role of AE3
protein in the development of cardiomyocyte hypertrophy. Mouse hearts were assessed by echocardiography. As
well, responses of cultured cardiomyocytes to hypertrophic stimuli were measured. pH regulation capacity of ae3−/−
and WT cardiomyocytes was assessed in cultured cells loaded with the pH-sensitive dye, BCECF-AM.
Results: ae3−/− mice were indistinguishable from wild type (WT) mice in terms of cardiovascular performance.
Stimulation of ae3−/− cardiomyocytes with hypertrophic agonists did not increase cardiac growth or reactivate the
fetal gene program. ae3−/− mice are thus protected from pro-hypertrophic stimulation. Steady state intracellular pH
(pHi) in ae3
−/− cardiomyocytes was not significantly different from WT, but the rate of recovery of pHi from imposed
alkalosis was significantly slower in ae3−/− cardiomyocytes.
Conclusions: These data reveal the importance of AE3-mediated Cl−/HCO3
− exchange in cardiovascular pH
regulation and the development of cardiomyocyte hypertrophy. Pharmacological antagonism of AE3 is an attractive
approach in the treatment of cardiac hypertrophy.
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Heart failureBackground
Cardiovascular diseases remain a major cause of death
worldwide despite progress in disease outcomes of pa-
tients [1]. Heart failure (HF) is the common end-stage of
many cardiovascular disorders, with a prevalence of 5.8
million in the USA and about 23 million worldwide [2,3].
Annually, 550,000 new cases of HF arise in the U.S.A. The
intricate molecular events resulting in heart failure remain
incompletely understood, but enlargement of cardiac* Correspondence: joe.casey@ualberta.ca
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unless otherwise stated.contractile cells (cardiomyocyte hypertrophy) in response
to various stimuli is central to the progression to heart
failure [4].
Cardiac cells are terminally differentiated cells that re-
spond to increased stress by increasing their size rather
than mitotically dividing to increase their number [5].
Cardiovascular events that increase myocardial stress
(workload) chronically induce hypertrophic growth. Pres-
sure overload, myocardial infarction, obesity, pregnancy or
exercise can independently trigger molecular mechanisms
culminating in increased cardiomyocyte size. Cardiac
hypertrophy occurs to normalize the elevated demand
on the myocardium, and can be physiological orLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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stimuli [6]. Physiological hypertrophy prevails in healthy
individuals during increased physical activities or in
pregnant women. Pathological hypertrophy results from
prolonged elevated blood pressure (pressure overload),
ischemia accompanied by changes in Ca++ handling, or
genetic abnormalities. Initially, pathological hypertrophic
growth compensates for the decline in contractile func-
tion, but ultimately the myocardium becomes decompen-
sated from sustained exposure to the initiating stimuli.
Understanding the distinct pathways mediating cardiac
hypertrophic development has potential to identify new
drug targets for the management of heart failure.
Intracellular pH (pHi) regulation is paramount in main-
taining normal cardiac function [7,8]. Plasma membrane
transporters involved in maintaining pHi at physiological
levels in the heart include the Na+/H+ exchanger (NHE1),
Na+/HCO3
− co-transporters (NBC), and Cl−/HCO3
− ex-
changers [9,10]. Cytosolic acidification or hormonal
stimulation activate NHE1, which facilitates electroneutral
Na+/H+ exchange, to alkalinize the cytosol [11]. Accumu-
lating evidence suggests that NHE1 expression level and
activity increase in hypertrophy [12,13]. In the hypertro-
phied myocardium of the spontaneously hypertensive rats
(SHR), there was an increased activation of NHE1 [14]
and NHE1 inhibition reduced cardiac hypertrophy and
interstitial fibrosis [15]. Transgenic mice expressing acti-
vated NHE1 exchanger had enlargement of the heart and
increased sensitivity to hypertrophic stimulation [16].
Since NHE1 activation induces acid extrusion, alkaliniza-
tion should accompany NHE1 activation. NHE1 activation
was not, however, accompanied by increased pHi, al-
though cytosolic Na+ was elevated [14]. Moreover, under
alkaline conditions, NHE1 activity is self-inhibited, which
suggests that an acidifying mechanism running counter to
NHE1 is necessary for sustained NHE1 activation [17-20].
Indeed, Cl−/HCO3
− exchange mediated by AE3 provides
this acidifying pathway [7,8,10].
The heart expresses three Cl−/HCO3
− exchanger
isoforms: AE1, AE2 and AE3 [10,21]. Another cardiac
Cl−/HCO3
−, SLC26a6, [22-24], may represent the Cl−/
OH− exchanger (CHE) that has been reported in the
heart [25]. Two AE3 variants, AE3 full length (AE3fl)
and cardiac AE3 (AE3c) are expressed in the heart;
AE3fl is also expressed in the brain and retina [26-28].
Phenylephrine (PE) and angiotensin II (ANGII), acting
on their G-protein-coupled receptors (GPCRs), activate
AE3fl via protein kinase C (PKC). Interestingly, PKC
can indirectly activate NHE1 via MAPK-dependent
mechanisms [29]. Moreover, carbonic anhydrase II
(CAII), another modulator of the PE-dependent hyper-
trophic growth, interacts with both NHE1 and AE3 to
provide their respective transport substrates, H+ and
HCO3
− [30,31].CAII activation was recently found to be important in
the induction of cardiomyocyte hypertrophy. In isolated
rat cardiomyocytes, inhibition of CAII catalytic activity
reduced phenylephrine (PE) and angiotensin II (ANGII)
induced cardiomyocyte hypertrophy [32]. Additionally,
infection of neonatal rat cardiomyocytes with adenoviral
constructs encoding catalytically inactive CAII mutant,
CAII-V143Y, reduced the response of the cardiomyo-
cytes to hypertrophic stimuli, suggested to arise from a
dominant negative mode of action [33]. Cardiomyocytes
from CAII-deficient mice had physiological hypertrophy,
but were unresponsive to hypertrophic stimulation [33].
Finally, expression of CAII and CAIV was elevated in
the hypertrophic ventricles from failing human hearts,
indicating that elevation of carbonic anhydrases is a fea-
ture of heart failure in people [34]. Taken together, these
findings show that CAII plays a role in the development
of cardiomyocyte hypertrophy.
Several reports revealed that CAII physically and func-
tionally interacts with Cl−/HCO3
− anion exchangers to
enhance the transport activity of anion exchangers form-
ing a bicarbonate transport metabolon [31,35-37], al-
though some reports have questioned the physiological
relevance of this physical and functional linkage [38-40].
CAII also interacts physically and functionally with
NHE1 to increase the exchange activity [30,41]. These
observations suggest that simultaneous activation of
AE3, CAII and NHE1 occurs upon pro-hypertrophic
stimulation by the PKC-coupled agonists, PE, ANGII or
endothelin I (ET-I). This pathological activated complex
has been termed the hypertrophic transport metabolon
(HTM) [34].
Accumulating evidence suggests a significant role of
AE3 in cardiac function. AE3 Cl−/HCO3
− exchange activ-
ity is involved in cardiac contractility by altering cardiac
Ca++ handling [42]. Moreover, disruption of the ae3 gene
in mice resulted in an exacerbated cardiac function and
precipitated heart failure in hypertrophic cardiomyopathy
mice [43]. Pacing of AE3 null hearts abrogated frequency-
dependent inotropy, which, suggests that AE3 is required
in mediating force-frequency response induced by acute
biochemical stress [44]. Taken together, these findings sug-
gest that the AE3 Cl−/HCO3
− exchanger is critical in heart
growth and function but the exact mechanism remains
unknown.
In the present study, we examined the role of AE3 in
cardiomyocyte hypertrophy, using AE3-deficient (ae3−/−)
mice. Cardiac growth parameters and fetal gene reactiva-
tion were measured in the presence of pro-hypertrophic
stimulation in cardiomyocytes from ae3−/− mice. We
also examined the role of AE3 in cardiomyocyte steady
state pHi, using the ae3
−/− mice. Our results indicate
that ae3 deletion prevents cardiomyocyte hypertrophy
and reduces the rate of pHi recovery in cardiomyocytes,
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pH regulation and the development of cardiomyocyte
hypertrophy.
Methods
Animal care and use
All procedures involving animals were performed in ac-
cordance with the guidelines established by the Canadian
Council on Animal Care and the University of Alberta
Animal Care and Use Committee.
ae3 null mice
Experiments were performed using ae3 null mice in a
C57BL/6 background. The ae3 null strain has been previ-
ously described and characterized [42]. Age-matched WT
mice from separate breedings were used as controls.
Heart weight to body weight ratio
Mice were weighed and anesthetized with sodium
pentobarbital (50 mg/kg) by intraperitoneal injection.
Upon reaching surgical plane, hearts were removed after
performing midsection thoracotomy and rinsed in 4°C
phosphate buffer saline (PBS: 140 mM NaCl, 3 mM KCl,
6.5 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.4). Ventricles
were separated from atria and blood vessels, blotted dry
and the ventricular weight was measured. Heart weight to
body weight ratio (HW/BW) was then calculated by divid-
ing the weight of the ventricles by the weight of the whole
animal.
Hematoxylin-eosin staining of heart sections
Hematoxylin and eosin (HE) staining was performed on
longitudinal and transverse sections of wildtype and ae3
null adult mouse heart, using previously described proto-
cols [45,46]. Briefly, paraffin-embedded hearts were sec-
tioned into 3 μm slices, which were trimmed and floated
onto a water bath at 42°C, containing 50 mg/l of gelatin
while gently stretching the cut sections to avoid wrinkles.
Poly-L-lysine coated microscope slides were dipped under
the meniscus of the water bath and a tissue slice was care-
fully mounted onto it. Sections were then air-dried for
16 h at 20°C, after which the slides were placed on edge in
an oven and baked for 15 min at 60°C. Sections were
deparaffinized by successively immersing them for 5 min
with agitation in xylene, 100% ethanol and 70% ethanol,
and rehydrated in Tris-EDTA buffer (1 mM EDTA, 0.05%
Tween 20, 10 mM Tris, pH 9.0) for 1 min. Slides were
rinsed in distilled water for 1 min with agitation. Slides
were agitated for 30 s in Mayer’s hematoxylin solution
(1.0 g/l hematoxylin (Sigma), sodium iodate (0.2 g/l),
aluminum ammonium sulfate · 12 H2O (50 g/l), chloral
hydrate (50 g/l) and citric acid (1 g/l) and rinsed in water
for 1 min. Slides were stained in 1% eosin Y solution (1%
eosin Y aqueous solution, Fisher) for 30 s with agitation.Sections were dehydrated by successively immersing it
twice in 95% ethanol and twice in 100% ethanol for 30 s
each. Ethanol was extracted twice in xylene, followed by
addition of two drops of mounting medium (Canada
Balsam, Sigma), after which the sections were covered
with a coverslip. Images of transverse and longitudinal
sections were collected, using a Nikon digital camera
(DXM 200) mounted on top of a Nikon Eclipse E600
microscope.
Echocardiography
Echocardiographic assessment of cardiac performance in
male WT and ae3−/− mice was performed by the Cardio-
vascular Research Centre Core Facility (University of
Alberta). Mice were subjected to mild anesthesia by iso-
flurane inhalation and echocardiography parameters
were measured using a Vevo 770 High-Resolution Im-
aging System with a 30-MHz transducer (RMV-707B;
Visual Sonics, Toronto). M-mode images and a four
chamber view allowed for the calculation of wall mea-
surements, ejection fraction, fractional shortening, and
mitral velocities (E and A). Mitral valve tissue motion
(E’) was measured, by tissue Doppler echocardiography
of the mitral septal annulus.
Blood pressure measurements
Non-invasive blood pressure measurements were per-
formed by the Cardiovascular Research Centre Core
Facility (University of Alberta). Mice were comfortably
restrained in a 26°C warming chamber (IITC Life
Science) for ~15 min prior to taking blood-pressure
(BP) measurements. Tail-cuff sensors were secured on
the tail to occlude the blood flow, and connected to the re-
cording device. Systolic and diastolic pressure, heart rate,
blood volume and flow were obtained, using CODA6 soft-
ware (Kent Scientific Corporation, Connecticut, USA).
Isolation and culture of adult mouse cardiomyocytes
Cardiomyocytes from adult male mouse hearts were
isolated and cultured with modifications of published
protocols [21,47]. Briefly, adult mice were euthanized
with sodium pentobarbital (50 mg/kg body mass) by
intraperitoneal injection. Upon reaching surgical plane,
midsection thoracotomy was performed and hearts
were quickly excised and placed in 4°C perfusion solu-
tion, containing in mM: 120 NaCl, 5.4 KCl, 1.2 MgSO4,
5.6 glucose, 10 2,3-butanedione monoxime (BDM) (Sigma),
5 taurine (Sigma), 1.2 NaH2PO4, 10 HEPES, pH 7.4.
Extra-cardiac tissues were removed and hearts were sub-
jected to retrograde perfusion with perfusion solution to
remove excess blood. Perfusion was switched for 15 min to
perfusion solution at 37°C, supplemented with 0.5 mg/ml
collagenase type B (Roche), 0.5 mg/ml collagenase type D
(Roche), 0.02 mg/ml protease XIV (Roche) and 50 μM
Table 1 Sequences of primers used in qRT-PCR
Target gene Primer sequence
Anp F: 5′-TCCAGGCCATATTGGAGCAAATCC-3′
R: 5′-TCCAGGTGGTCTAGCAGGTTCTTG-3′
β-mhc F: 5′-GAGACGGAGAATGGCAAGAC-3′
R: 5′-AAGCGTAGCGCTCCTTGAG-3′
Caii F: 5′-CTCTGCTGGAATGTGTGACCT-3′
R: 5′-GCGTACGGAAATGAGACATCTGC-3′
Nhe1 F: 5′-TTTTCACCGTCTTTGTGCAG-3′
R: 5′-TGTGTGGATCTCCTCGTTGA-3′
Gapdh F: 5′-CCTCGTCCCGTAGACAAAAT-3′
R: 5′-TGATGGCAACAATCTCCACT-3′
Anp, atrial natriuretic peptide; β-mhc , beta myosin heavy chain; Caii, carbonic
anhydrase II; F, Forward; Nhe1, sodium proton exchanger isoform 1; Gapdh,
glyceraldehyde 3-phosphate dehydrogenase; R, Reverse.
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moved, cut into several pieces, and digested further in the
same enzyme digestion solution by gentle trituration with
a transfer pipette. Once the ventricles were completely
digested, enzymatic digestion was terminated by addition
of Digestion stop buffer I (perfusion solution, containing
10% (v/v) fetal bovine serum (FBS) (GIBCO) and 50 μM
CaCl2). Lysates settled under gravity for 10 min at room
temperature and pellets were resuspended in myocyte
stopping buffer II (perfusion solution, containing 5% (v/v)
FBS and 50 μM CaCl2). Samples were transferred to
60 mm tissue culture dish and calcium levels were in-
creased by addition of CaCl2 to obtain final concentrations
of 62, 112, 212, 500 and 1000 μM, sequentially at 4 min
intervals at 20°C. Cells were transferred to a 14 ml culture
tube and allowed to sediment for 10 min under gravity.
Cells were resuspended in myocyte culture medium
(Dulbecco’s Modified Eagle’s Medium/Nutrient Mixture
F12-Ham (Sigma), supplemented with 10 mM BDM, 5%
(v/v) FBS, 1% penicillin (GIBCO), 10 mM BDM, and
2 mM L-glutamine (GIBCO)). Myocytes were plated at
a density of (0.5-1) x 104 cells/cm2 onto 35 mm culture
dishes, pre-coated for 2 h with 10 μg/ml mouse laminin
(Invitrogen) in PBS. Cells were incubated at 37°C in a
5% CO2 incubator for 1 h at which point medium was
replaced with Dulbecco’s Modified Eagle’s Medium/
Nutrient Mixture F12-Ham, containing 10 mM BDM,
1% penicillin, 2 mM L-glutamine, 0.1 mg/ml bovine
serum albumin, and 1x ITS Liquid Media Supplement
(Sigma). The entire culture procedure was carried out
in a sterile laminar flow hood.
Assessment of cardiomyocyte hypertrophic growth
Cardiomyocytes were isolated and cultured from adult
mouse hearts as described above. Following 18 h of cul-
ture, myocytes were treated with solvent carrier (control),
10 μM phenylephrine (Sigma) or 1 μM angiotensin II
(Sigma) for another 24 h. Hypertrophy was assessed by
analysis of cell surface area of cardiomyocytes pre- and
post-treatment with the hypertrophic agonists. Images
of characteristic rod-shaped cardiomyocytes were col-
lected with a QICAM fast-cooled 12-bit colour camera
(QImaging Corporation). Cell surface areas were mea-
sured, using Image-Pro Plus software (Media Cybernetics).
Each treatment group contained 100–200 cells of ~ ten
different experiments. Cell surface area (% relative to
control) = Surface area (post-treatment)/Surface area (pre-
treatment) X 100.
Real-time quantitative reverse transcription PCR
(qRT-PCR)
Cardiomyocytes were prepared and treated as above. At
the end of the culture period, medium was aspirated and
cardiomyocytes were harvested in 350 μl Buffer RLT(Qiagen). RNA was extracted from the lysates with an
RNeasy Plus Mini Kit, as per manufacturer’s instructions
(Qiagen). RNA samples (100 ng) were reverse transcribed,
following the manufacturer’s instructions for SuperScript
II™ reverse transcriptase (Invitrogen). qRT-PCR was
performed in a Rotorgene 3000 real time thermal cycler
(Corbett Research), using a reaction mix containing:
5 μl template cDNA, 12 μl 2x Rotor-Gene SYBR Green
PCR Master Mix (Rotor-Gene SYBR Green PCR Kit,
Qiagen), and 1 μM of each primer. Data were obtained
and analyzed, using Rotor Gene 6.0.14 software. Cycle
threshold (Ct) values were obtained for carbonic anhy-
drase II (CAII), NHE1, atrial natriuretic peptide (ANP),
β-MHC and glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH). Primers (Table 1) were designed, using
Primer3 (http://Frodo.wi.mit.edu/primer3/).
Immunoblotting
Cardiomyocytes, isolated and cultured from adult mouse
hearts, were subjected to drug intervention as described
above. Twenty-four h following treatment, medium was
aspirated and myocytes were washed with 4°C PBS. Cells
were lysed with SDS-PAGE sample buffer (10% (v/v)
glycerol, 2% (w/v) SDS, 2% 2-mercaptoethanol, 0.001%
(w/v) bromophenol blue, 65 mM Tris, protease inhibi-
tors (1 μg/ml) pH 6.8) and lysates were heated 5 min at
65°C. Protein concentrations were determined by the
bicinchoninic acid (Pierce Biotechnology) assay [48],
and 20 μg of protein was resolved by SDS-PAGE on
10% acrylamide gels. Proteins were transferred onto
PVDF membranes by electrophoresis for 1 h at 100 V in
transfer buffer (10% (v/v) methanol, 25 mM Tris, and
192 mM glycine). PVDF membranes were blocked for
30 min with 5% (w/v) nonfat dry milk/ 0.1% (v/v) Tween
20 in TBS (137 mM NaCl, 20 mM Tris, pH 7.5). Immu-
noblots were incubated with rabbit polyclonal anti-CAII
antibody (Santa Cruz Biotechnology; 1:1000), rabbit
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anti-NHE1 antibody (1:1000) [32] in TBST-M for 16 h
at 4°C. Immunoblots were washed with TBST (TBS,
containing 0.1% (v/v) Tween 20) and incubated with
donkey anti-rabbit IgG conjugated to horseradish peroxid-
ase (Santa Cruz Biotechnology; 1:2000) or mouse anti-
goat IgG conjugated to horseradish peroxidase (Santa
Cruz Biotechnology; 1:2000) for 1 h at room temperature.
Immunoblots were washed in TBST and visualized, using
ECL reagents (Perkin Elmer) and a Kodak Imaging Station
440CF (Kodak, Rochester, NY). Proteins were quantified
by densitometry, using Kodak Molecular Imaging software
(version 4.0.3; Kodak). Immunoblots were stripped by in-
cubating in 10 ml of stripping buffer (2% (w/v) SDS,
10 mM 2-mercaptoethanol, 62.5 mM Tris, pH 6.8) at 50°C
for 10 min with occasional shaking, followed by three
washes with TBST. Membranes were incubated with
mouse monoclonal anti-β-actin antibody (Santa Cruz
Biotechnology; 1:2000) for 1 h at 20°C, washed with
TBST, and incubated with sheep anti-mouse IgG conju-
gated to horseradish peroxidase (Santa Cruz Biotech-
nology; 1:3000) for 1 h. Immunoblots were washed and
visualized again, as described above.
Protein synthesis assays
Cardiomyocytes were prepared and subjected to hyper-
trophic stimulation as above. Radiolabeled phenylalanine
([3H]-Phe, 1 μCi/ml, (Perkin Elmer)) was added imme-
diately after drug intervention and cells were incubated
for another 24 h. Proteins were precipitated, using
trichloroacetic acid (TCA) as described previously with
some modifications [50]. Medium was carefully aspi-
rated and 500 μl of 0.5% (v/v) Triton X-100, containing
protease inhibitor cocktail (Roche) were added. Lysates
were transferred into 1.5 ml microcentrifuge tubes and
TCA (100%: 500 g in 350 ml H2O) was added to each
tube to a final concentration of 40% (v/v). Samples were
incubated at 4°C for 30 min, after which proteins were
sedimented by centrifugation at 12 682 x g for 15 min
at 4°C. Pellets were resuspended by adding 200 μl acet-
one (−20°C) and sedimented again by centrifugation, as
above, for 10 min. The acetone wash was repeated one
more time, and the pellets air dried for 20 min at room
temperature. Pellets were resuspended in 200 μl of
0.2 M NaOH, 1% (w/v) SDS. Scintillation fluid (Perkin
Elmer, 3.5 ml) was added to each sample and the radio-
activity of [3H]-Phe was counted in a Beckman LS6500
liquid scintillation counter.
Measurement of pHi in adult mouse cardiomyocytes
The protocol was as described previously with minor
modifications [51,52]. Briefly, cardiomyocytes were iso-
lated as described above and cultured on laminin-coated
glass coverslips. Approximately 2 h later, cells were loadedwith 2 μM BCECF-AM (Sigma-Aldrich, Canada) for
30 min at 37°C. Coverslips were placed in an Attofluor
cell chamber (Invitrogen, Canada), then transferred
onto the stage of a Leica DMIRB microscope. Perfusion
with HCO3
− Ringer’s buffer solution (in mM: 128.3
NaCl, 4.7 KCl, 1.35 CaCl2, 20.23 NaHCO3, 1.05 MgSO4
and 11 glucose, pH 7.4) was initiated at 3.5 ml/min.
Solutions were bubbled with 5% CO2-balanced air.
Intracellular alkalosis was induced by switching to a
HCO3
− Ringer’s solution, containing, 20 mM trimethy-
lamine (TMA) (Sigma) and perfusion was continued for
3 min. Perfusion was switched back to the HCO3
−
Ringer’s buffer solution. pHi of individual cardiomyocytes
was measured by photometry at excitation wavelengths of
502.5 nm and 440 nm with a Photon Technologies
International (PTI, Lawrenceville, NJ, USA) Deltascan
monochromator. Emission wavelength, 528.7 nm, was
selected, using a dichroic mirror and narrow range filter
(Chroma Technology Corp., Rockingham, VT, USA) and
was measured with a PTI D104 photometer. At the end of
experiments, pHi was clamped by the high K
+/Nigericin
technique [53] in calibration solutions containing,
140 mM KCl, 1 mM MgCl2, 2 mM EGTA, 11 mM
glucose, 20 mM BDM, 10 mM HEPES. Three pH
standards spanned a range of 6.5-7.5. Steady-state
pHi was measured from the pHi value prior to in-
duction of alkalosis. Rate of pHi recovery was mea-
sured by linear regression from first min of recovery
from imposed alkalosis.Statistical analysis
Data are expressed as mean ± S.E.M. Statistical analyses
were performed using paired t-tests or ANOVA where
appropriate. P < 0.05 was considered significant.Results
Cardiac development in ae3−/− mice
To examine the role of AE3 in heart development, we
characterized age-matched wildtype (WT) and ae3−/−
mice (~three months old). Breeding yielded Mendelian
ratios of litters of both WT and ae3−/− mice, indicating
that loss of the AE3 does not affect prenatal survival.
While the body weights of age-matched WT and ae3−/−
mice were not significantly different (Figure 1A), the
difference in heart weights between the groups was sta-
tistically significant (Figure 1B). As a result, the HW/
BW ratio, an index of cardiac hypertrophy, was reduced
in the ae3−/− mice relative to their WT counterparts
(Figure 1C and D), suggesting that AE3 has a role in
heart growth. Despite the observed apparent smaller
size of the ae3 null hearts, gross morphology of hearts
stained with hematoxylin/eosin transverse and longitu-
dinal sections revealed no differences in the wall size
*40
35
30
5
10
15
20
25
0
0.14
0.12
0.10
0
0.02 
0.04
0.06
0.08
A B
C
B
od
y 
W
ei
gh
t (
g)
H
ea
rt
 W
ei
gh
t (
g)
H
ea
rt
 W
ei
gh
t/ 
B
od
y 
W
ei
gh
t 
ae3+/+ ae3+/- ae3-/-
0.004
0.001
0.002
0.003
0
*
ae3-/-ae3+/-ae3+/+
ae3+/+ ae3+/- ae3-/-
Figure 1 Heart weight to body weight ratio of mice. A, Body weights (BW) of the AE3 null (ae3-/-, black bar), heterozygous (ae3+/-, red bar)
and the WT (ae3+/+, open bar) littermates were measured. B, Hearts, surgically removed from anaesthetized mice and trimmed of extra-cardiac
and atrial tissue, were measured to obtain the ventricular weight (heart weight, HW). C, HW/BW, an index of hypertrophy, was calculated. *P<0.05
(n=8 mice/ group).
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null (right panel) mouse hearts (Figure 2B-C).
Blood pressure and echocardiography
Cardiovascular performance of age-matched WT and
ae3−/− mice was assessed by echocardiography. No major
variations in cardiovascular functional parameters between
WT and ae3−/− mice (~three months old males) were ob-
served, except for a significant decrease in the mitral value
E/A ratio in ae3−/− mice (Table 2). While this would sug-
gest that more blood is entering the ventricle during the
atrial systolic phase than during ventricular relaxation,
other parameters of diastolic cardiac function (E/E’ ratio,
IVRT) were unaffected. ae3−/− mice therefore likely do not
exhibit diastolic dysfunction. Systemic blood pressure
measurements were also performed using the non-
evasive tail cuffing approach. No significant difference
in the systemic blood pressure of WT and ae3−/− mice
was observed (Table 2). Overall, these observations
suggest that loss of AE3 does not affect cardiovascular
performance under basal conditions, consistent with
previous findings [42,44].Cardiomyocyte growth upon pro-hypertrophic
stimulation
Cardiomyocyte hypertrophy is characterized by an increase
in cardiomyocyte surface area, resulting in an overall in-
crease in heart size. Cardiomyocytes were isolated from
adult WT and ae3−/− mice and the cell surface assessed by
morphometry. The cell surface area of ae3 null cardio-
myocytes was 20% ± 4% (n = 6) lower than WT (Figure 3).
To determine the response of cardiomyocytes to pro-
hypertrophic stimulation, adult cardiomyocytes were cul-
tured and treated with PE and ANGII 18 h later. Cell
surface area was measured 24 h following treatment with
hypertrophic agonists. PE and ANGII induced a 20–25 ±
4% (n = 10) increase in the cell surface area of WT cardio-
myocytes, but cardiomyocytes from ae3−/− hearts were not
susceptible to pro-hypertrophic stimulation by these agents
(Figure 4). This suggests that AE3 has a role in the hyper-
trophic signaling pathway downstream of PE and ANGII.
Expression of hypertrophic marker genes
Cardiac hypertrophic development is associated with
increased expression of marker genes, including ANP
AB
C
ae3+/+ ae3-/-
Figure 2 Cross-sections of heart from WT and ae3−/− mice. Whole hearts were removed from euthanized mice and atrial tissue was excised
(A). Longitudinal (B) and transverse (C) sections of the ventricle from ae3−/− (Right Panel) and ae3+/+ (Left Panel) hearts were stained with
hematoxylin/eosin.
Sowah et al. BMC Cardiovascular Disorders 2014, 14:89 Page 7 of 16
http://www.biomedcentral.com/1471-2261/14/89[54], β-myosin heavy chain (β-MHC) [55] and α-skeletal
actin [56]. mRNA and protein levels of these markers are
elevated in hypertrophic hearts [57]. Expression levels of
ANP and β-MHC, were assessed by qRT-PCR in cardio-
myocytes subjected to pro-hypertrophic stimulation.
Transcript abundance of ANP and β-MHC were notsignificantly different between untreated cardiomyocytes
from WT and ae3−/− mice (Figure 5A and B). Stimulation
with PE and ANGII, however, led to 8–10 fold increase of
ANP and β-MHC expression levels in cardiomyocytes
from WT mice. In contrast, ANP and β-MHC increased
only 1–2 fold in cardiomyocytes from ae3−/− mice. These
Table 2 Echocardiographic and blood pressure analysis of
WT and ae3−/− mice
Parameter WT ae3−/−
Ejection fraction, % 65 ± 3 67 ± 7
Fractional shortening, % 35 ± 3 37 ± 7
IVSd, mm 0.70 ± 0.01 0.75 ± 0.04
LVIDd, mm 3.5 ± 0.1 3.4 ± 0.1
LVPWd, mm 0.67 ± 0.03 0.70 ± 0.03
IVSs, mm 1.08 ± 0.03 1.11 ± 0.09
LVIDs, mm 2.3 ± 0.1 2.1 ± 0.3
LVPWs, mm 1.05 ± 0.07 1.05 ± 0.12
MV E Velocity, mm.s−1 730 ± 50 710 ± 50
MV A Velocity, mm.s−1 390 ± 30 520 ± 40
MV E/A ratio 1.9 ± 0.1 1.4 ± 0.1
E/E’ 24 ± 3 21 ± 4
IVRT, ms 16 ± 0 17 ± 2
TEI index 0.63 ± 0.03 0.61 ± 0.02
Systolic pressure, mm Hg 102 ± 7 100 ± 9
Diastolic pressure, mm Hg 66 ± 6 64 ± 8
Flow, ml.min−1 11 ± 1 10 ± 1
Volume of blood, ml 36 ± 6 31 ± 5
Heart rate, beats.min−1 699 ± 1 721 ± 49
All experiments were performed on male mice. Values are expressed as
means ± S.E.M. (n = 3 per group for echocardiography; n = 7 for tail cuff
parameters, with three replicates over three separate days (bottom five rows
of the table)); P < 0.05. IVSd, diastolic intraventricular septal wall thickness;
LVIDd, diastolic left ventricular internal diameter; LVPWd, diastolic left
ventricular posterior wall thickness; IVSs, systolic intraventricular septal wall
thickness; LVIDs, systolic left ventricular internal diameter; LVPWs, systolic left
ventricular posterior wall thickness; MV E velocity, peak E wave mitral valve
velocity; MV A velocity, peak A wave mitral valve velocity; MV E/A, ratio of
peak E wave mitral valve velocity to peak A wave mitral valve velocity; E/E’,
ratio of peak E wave mitral valve velocity to E wave mitral valve tissue motion;
IVRT, isovolumic relaxation time.
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http://www.biomedcentral.com/1471-2261/14/89data suggest that pro-hypertrophic stimulation induces
a much greater upregulation of hypertrophic marker
genes in cardiomyocytes from WT mice than ae3−/−
cardiomyocytes.
Expression of HTM genes in mouse cardiomyocytes
AE3 is implicated as part of a functional complex with
NHE1 and CAII, referred to as the hypertrophic trans-
port metabolon (HTM), whose activation has been pro-
posed to induce cardiac hypertrophy [32,33]. To assess
the possibility of functional compensation for loss of
AE3 by altered expression of these partner proteins, we
examined mRNA expression of NHE1 and CAII by qRT-
PCR. Baseline expression level of NHE1 in ae3−/− mice
was significantly elevated compared to the WT mice
(Figure 6A). Pro-hypertrophic stimulation with PE or
ANGII did not influence the NHE1 transcript abun-
dance in the WT or ae3−/− cardiomyocytes (Figure 6A).
CAII transcript abundance, however, was higher incardiomyocytes from ae3−/− mice than from WT mice
(Figure 6B). ae3 ablation thus induces a compensatory
increase in CAII expression. Interestingly, pro-hypertrophic
stimulation markedly increased CAII transcript levels in
both WT and ae3−/− cardiomyocytes (Figure 6B).
Since the baseline expression level of CAII was elevated
in ae3−/− cardiomyocytes and was further enhanced by
hypertrophic stimulants in WT cardiomyocytes, we evalu-
ated CAII protein expression. Cardiomyocytes isolated
from ae3−/− and WT male adult mice hearts were probed
for CAII on immunoblots (Additional file 1: Figure S1A).
CAII migrated at ~27 kDa, consistent with the expected
molecular weight of CAII. Both the steady-state level of
CAII protein (Additional file 1: Figure S1B) and mRNA
level for CAII (Figure 6B) were higher in ae3−/− cardio-
myocytes than WT cardiomyocytes. Importantly, however,
there was a large quantitative difference in the response,
where CAII protein level rose by about 50%, whereas CAII
message rose was about eight-fold higher in the ae3−/−
mice than WT. PE and ANGII increased CAII levels in the
WT cardiomyocytes. Contrastingly, CAII levels in ae3−/−
cardiomyocytes were not significantly affected by pro-
hypertrophic stimulation (Additional file 1: Figure S1B).
Protein synthesis in pro-hypertrophically-stimulated
cardiomyocytes
Cardiac hypertrophy is also characterized by an increase
in protein synthesis to accommodate cardiomyocyte en-
largement [58]. Protein synthesis was measured by deter-
mining the amount of radioactive [3H]-Phe incorporated
into proteins in cardiomyocytes, isolated and cultured
as described above and treated with PE and ANGII.
[3H]-Phe incorporation into proteins in the presence of
pro-hypertrophic stimuli was increased in cardiomyo-
cytes from WT, but not ae3−/− mice. We conclude that
ae3−/− mice do not respond to pro-hypertrophic agonists
with increased protein synthesis (Figure 7).
pHi regulation in mouse cardiomyocytes
AE3 contributes to cardiomyocyte pHi regulation [59-61],
but there are no AE3-specific inhibitors that would enable
delineation of the role of AE3 in pHi regulation. We thus
examined the rate of recovery of pHi from an imposed
intracellular alkalinization in freshly isolated cardiomyo-
cytes. Cardiomyocytes were cultured on laminin-coated
glass coverslips for 2 h, then incubated with the pH-
sensitive fluorescence dye, BCECF-AM. Cells were per-
fused with a HCO3
−-containing Ringer’s buffer until
steady-state pHi was reached and the perfusion was
switched to the HCO3
−-containing Ringer’s buffer, con-
taining TMA. The presence of TMA induced a rapid
intracellular alkalinization (Figure 8A) until a new steady-
state pHi was reached. pHi regulatory transporters
spontaneously restored cell pHi. Steady-state pHi was
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Figure 4 Effect of hypertrophic stimuli on cardiomyocyte size. Cardiomyocytes isolated from the ventricles of WT (ae3+/+) (A) and ae3−/−
(B) adult mice were subjected to vehicle alone (control), ANGII (1 μM) and PE (10 μM) treatment for 24 h, following an 18 h pre-treatment period.
Images of the cardiomyocytes, taken pre- and post-treatment using a QICAM fast cooled 12-bit color camera, were quantified to measure the cell
surface area. In the control group, equal volume of the vehicle was added. C, Cell surface areas were expressed as a percentage of vehicle-treated
control groups (open bars) and compared to the ANGII (black bars) and PE (blue bars) treated groups. *P < 0.05, relative to control group (n = 10
mice in each group).
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Figure 3 Cardiomyocyte size in WT and ae3−/− mice. Cardiomyocytes were isolated from male adult hearts of wildtype (ae3+/+, open bar) and
knock-out (ae3−/−, black bar) mice. Total cell surface area of rod-shaped cardiac cells was determined by morphometry. Data are expressed as a
percentage relative to the wildtype cells. * P < 0.05 compared to WT (n = 6 mice in each group).
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Figure 5 Effect of hypertrophic stimuli on expression of hypertrophic marker mRNA. Cardiomyocytes were isolated from ae3−/− and ae3+/+
adult mouse hearts and maintained in cell culture. Following 18 h culture period, vehicle alone (control, open bars), ANGII (1 μM, black bars) or
PE (10 μM, blue bars) were added for further 24 h. To determine the mRNA expression levels of ANP or β-MHC, quantitative real-time PCR was
performed. RNA prepared from cardiomyocytes was reverse transcribed and the resulting cDNA was subjected to qRT-PCR. Cycle threshold (Ct)
value was obtained for ANP or β-MHC and GAPDH. Ct values of each sample were corrected for the respective GAPDH Ct values. Absolute
differences in gene expression between samples is based on the relation that a difference of one cycle corresponds to a difference of two-fold in
template abundance. Relative transcript abundance was expressed as fold-change of ANP (A) or β-MHC (B) relative to control. *P < 0.05,
compared to control group (n = 4).
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http://www.biomedcentral.com/1471-2261/14/89measured as the pHi 60 s prior to switching to the
TMA-supplemented HCO3
−-containing Ringer’s buf-
fer. The rate of pHi recovery from imposed intracellu-
lar alkalinization was measured by linear regression of
the initial minute of pHi recovery. Baseline pHi was
identical in cardiomyocytes from WT and ae3−/− mice
(Figure 8B). The mean peak pH following alkalization for
WT group was 7.65 ± 0.05 and 7.60 ± 0.06 for ae3−/− mice.
Thus, under basal physiological conditions, loss of AE3
does not significantly affect the steady-state pHi in car-
diomyocytes. The rate of recovery of pHi from alkalosiswas, however, significantly slower in ae3−/− cardiomyo-
cytes than WT (Figure 8C).
Expression of pHi regulators in ae3
−/− cardiomyocytes
We next assessed the expression level of the other pHi
regulatory transporters at the protein level. On immuno-
blots the proteins migrated at the expected sizes, NHE1
at ~100 kDa, and SLC26a6 at ~80 kDa (Additional file 2:
Figure S2 and Additional file 3: Figure S3). Consistent
with a previous study [44], expression of NHE1 was ele-
vated in ae3−/− cardiomyocytes compared to WT, but
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Figure 6 Effect of hypertrophic stimuli on expression of CAII
and NHE1 mRNA. Cardiomyocytes were isolated from ae3−/− and
ae3+/+ adult mouse hearts. Following 18 h culture period, vehicle
(open bar, control), ANGII (1 μM, black bars) or PE (10 μM, blue bars)
were added for further 24 h. To determine the mRNA expression
levels of NHE1 or CAII, quantitative real-time PCR was performed.
RNA prepared from cardiomyocytes was reverse transcribed and the
resulting cDNA was subjected to qRT-PCR. Cycle threshold (Ct) value
was obtained for NHE1 or CAII and GAPDH. Ct values of each sample
were corrected for the respective GAPDH Ct values. Absolute
differences in gene expression between samples is based on the
relation that a difference of one cycle corresponds to a difference of
two-fold in template abundance. Relative transcript abundance was
expressed as fold-change of NHE1 (A) or CAII (B) relative to control.
*P < 0.05, compared to ae3+/+ control group. # P < 0.05, compared
to ae3−/− control group (n = 4).
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Figure 7 Effect of hypertrophic stimuli on protein synthesis.
Cardiomyocytes were isolated from both ae3−/− and ae3+/+ (wildtype)
adult mice heart. Following 18 h culture period, vehicle (open bars,
control), ANGII (1 μM, black bars) and PE (10 μM, blue bars) were
added for further 24 h. Radiolabeled phenylalanine ([3H]-Phe, 1 μM),
was added immediately after drug intervention and cells were
incubated for further 24 h. Cells were harvested and proteins were
precipitated by TCA precipitation. Incorporated [3H]-Phe was measured
by scintillation counting and expressed relative to the vehicle control
group as a percentage. *P < 0.05 compared to control group (n = 5).
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http://www.biomedcentral.com/1471-2261/14/89remained unchanged in the heterozygotes (Additional
file 2: Figure S2A-B). Expression of SLC26a6 protein was
not affected by deletion of the ae3 gene (Additional
file 3: Figure S3A-B).
Discussion
Pathological cardiac hypertrophy renders the heart suscep-
tible to cardiac failure. Accumulating evidence implicates
NHE1 as a key candidate mediating pathological hyper-
trophy. Prolonged NHE1 activation produces intracellular
alkalinization. Sustained NHE1 activation can only
occur in the presence of a counter acidifying mechan-
ism. The present study examined the possibility thatthe Cl−/HCO3
− anion exchange mediated by AE3 is re-
sponsible for the acidification mechanism. Our studies,
using AE3 deficient mice, support a role for AE3 in
cardiovascular pH regulation and the development of
hormonally-induced cardiomyocyte hypertrophy. Pharma-
cological antagonism of AE3 is thus a possible therapeutic
direction in the prevention of maladaptive cardiac
hypertrophy.
Role of AE3 in cardiomyocyte hypertrophy
The role of AE3 in cardiac physiology is incompletely
characterized, but several lines of evidence suggest that
AE3 Cl−/HCO3
− exchange is required to maintain pHi
homeostasis [10,61]. Consistent with this, we found that
the rate of recovery from an alkaline load was reduced
in ae3−/− cardiomyocytes, relative to WT.
The hypertrophic transport metabolon is a proposed
pathological pathway in which AE3, NHE1 and CAII are
coordinately activated and promote hypertrophic growth
[32,33]. Specifically, pro-hypertrophic agonists, including
PE, ANGII and endothelin are coupled to PKC activa-
tion. NHE1 and AE3 are both activated by agonists
coupled to PKC activation [59,62,63]. Co-activation of
these respective alkalinizing and acidifying transporters
has the net effect of loading the cell with NaCl, with no
change of cytosolic pH. Elevated cytosolic Na+ in turn
reduces the efficacy of Ca++-efflux by the plasma mem-
brane Na+/Ca++ exchanger, resulting in a rise in cytosolic
Ca++. Ca++ is a pro-hypertrophic second messenger
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Figure 8 Intracellular pH regulation in ae3−/− cardiomyocytes. Freshly isolated cardiomyocytes were loaded with 2 μM BCECF-AM for 30 min,
placed in an Attofluor cell chamber and mounted onto an inverted epifluorescence Leica DMIRB microscope. A, In this representative experiment,
WT cardiomyocytes were perfused with HCO3
−-containing Ringer’s buffer (open bar) until steady-state pH was reached and perfusion was
switched to HCO3
−-containing Ringer’s buffer supplemented with 20 mM TMA (black bar). Perfusion was switched to the HCO3
−-containing Ringer’s
buffer ~3 min later. At the end of the perfusion pHi was clamped by the high K
+/nigericin technique to convert fluorescent intensities to pHi (not
shown). B, Steady-state pHi was measured as the pHi value prior to induction of intracellular alkalosis. C, The rate of recovery of pHi from imposed
alkalosis was assessed as the first minute of pHi recovery fitted by linear regression. *P < 0.05 compared to WT (ae3
+/+) (n = 4).
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http://www.biomedcentral.com/1471-2261/14/89[64,65] and also may promote hypertrophy in a feed-
forward cascade by stimulation of PKC [6]. Accumulat-
ing evidence suggests that both NHE1 and AE3 activities
are influenced by physical and functional interactions
with CAII [32,41], which provides substrates for these
transporters. That said, very recent data suggest that intra-
cellular carbonic anhydrase does not activate cardiomyo-
cyte Na+/H+ exchange [66]. Prevention of PE-induced
cardiomyocyte hypertrophy upon CAII blockade [32,33]
may thus arise from reduced AE3-mediated cytosolic
acidification, thereby decreasing driving force for NHE-
mediated alkalinization. We propose that CAII, NHE1
and AE3 form a hypertrophic transport metabolon,
where hypertrophy is promoted by the pathological acti-
vation of AE3 and NHE1, stimulated by interactions
with CAII.
The functional relationship between AE3, CAII and
NHE1 was further supported by our analysis of protein
expression in ae3−/− mice. Increased CAII transcript
abundance and protein expression in ae3−/− mice com-
pared to WT mice suggest that there is compensationfor a loss of AE3. This finding parallels results in retinal
tissue from ae3−/− mice, where there was increased CAII
expression [67]. Functional complementarity of AE3 and
CAII is further supported by the significant increase
in AE3 transcript abundance in Car2 (caii−/−) mice,
compared to WT mice [33]. The upregulation of NHE1
transcript abundance and increased protein expression
provide further support for the HTM. Taken together,
these data support a functional interaction between AE3
and CAII, where there is compensation of one for the
loss of the other.
Loss of AE3 prevents cardiomyocyte hypertrophy
This study lends support to the idea that AE3 is the Cl−/
HCO3
− exchanger isoform working in conjunction with
NHE1 to promote cardiomyocyte hypertrophy. Non-
specific inhibition of Cl−/HCO3
− exchangers, using
stilbene derivatives, prevented hypoxia-induced acidifi-
cation in rat ventricular myocytes, as well as increases
in intracellular Cl− and Ca++ concentrations [68,69],
suggesting a role of Cl−/HCO3
− exchangers in cardiac
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http://www.biomedcentral.com/1471-2261/14/89pathology. When subjected to ischemia and reperfusion,
hearts isolated from ae3−/− mice revealed no effect on car-
diac performance demonstrated as contractility, ventricu-
lar developed pressure or end diastolic pressure relative to
wildtype [42]. Double knock-out ae3/nkcc1 (Na+-K+-2Cl−
co-transporter) mice, however, had elevated ischemia/
reperfusion injury, which resulted in impaired cardiac
contractility and overall cardiac performance [42]. These
findings were attributed to impaired Ca++ handling in the
double knock-out cardiomyocytes [42] compared to the
single mutants. In a hypertrophic cardiomyopathy mouse
model carrying a Glu180Gly mutation in α-tropomyosin
(TM180), disruption of ae3 did not prevent or reverse the
hypertrophic phenotype [43]. The TM180/ae3 double
knockout mice had reduced cardiac function and com-
promised Ca++ regulation, which accounted for the
rapid decline to heart failure [43].
Taken together, these two studies suggest that AE3 loss
is not cardioprotective, which contrasts with findings of
the present study, which found that loss of AE3 renders
cardiomyocytes less susceptible to pro-hypertrophic sti-
mulation. Our data showed that the marked rise in cell
surface area, protein synthesis, and fetal gene reactivation
observed in response to hypertrophic stimulation in cardi-
omyocytes from WT mice was not present in ae3−/− mice.
In the context of cardiomyocyte hypertrophy mediated
by hormonal stimuli, our data demonstrate that abla-
tion of AE3 affords protection against cardiomyocyte
hypertrophy.
The discrepancy could arise from the model of hyper-
trophy and the cardiac pathology being investigated.
Hypertrophic cardiomyopathy is a genetic disorder, which
occurs as a result of mutations in the genes that encode
cardiac contractile proteins [70]. This anomaly manifests
as sudden cardiac death, arrhythmias, hypertrophy and
heart failure [70]. Overall, hypertrophic cardiomyopathy
results in impairment of Ca++ sensitivity by the myofibrils.
In the present study however, we employed a model of
hypertrophy induced by PE or ANGII, which involves
interaction of these ligands with their cell surface recep-
tors, GPCR [71]. The resultant intracellular response
leads to increased cytosolic Ca++ overload, which me-
diates a cascade of signaling pathway involving activa-
tion of PKC, which ultimately induces cardiomyocyte
hypertrophy [72].
One other possible explanation for the discrepancy be-
tween the present findings and earlier studies of ae3−/−
mice is the assay of cardiac hypertrophy. Earlier investiga-
tions probed whole animal physiology, whereas we studied
isolated cardiomyocytes in culture. Isolated cardiomyo-
cytes are an established model, which may be more sen-
sitive in detecting alterations of heart cell growth than
assessments of functional alterations of heart function
sued in earlier studies.Interestingly, AE3 also forms a complex with CAXIV
in the myocardium [73]. In the hypertrophic myocardium
of SHR rats, exacerbated AE3/CAXIV activation was pro-
posed to elicit hypertrophic growth of the heart [73].
Thus, the etiology, signaling pathway and pathophysiology
of hypertrophic cardiomyopathy are distinct from that
mediated by hormonal factors. These differences could ac-
count for the disparity between the influence of AE3 on
hypertrophy in the present report and that shown in previ-
ous models of cardiovascular disease [42,43]. Since hyper-
trophic interventions by PE and ANGII failed to induce
hypertrophy in the ae3 null cardiomyocytes in our study,
the PKC-coupled hypertrophic cascade appears to require
AE3. Recently, it was demonstrated that when paced, AE3
null hearts had an impaired force-dependent inotropy
characterized by an elevation of protein kinase B (PKB,
Akt) phosphorylation and a downregulation of AMPK
activity [44]. This observation may provide additional
support of the present findings that revealed that ae3
null cardiomyocytes are less susceptible to develop
hypertrophy in upon pro-hypertrophic stimulation. Akt
phosphorylation is central to the signaling pathway
mediated by growth factors that induce physiological
hypertrophy [57]. Thus, its activation under stressful
conditions may trigger a physiological growth response
to counter the pathological signaling cascade stimulated
the source of stress. The lack of response by the AE3
knock-out cardiomyocytes to hypertrophic stimulants
seen here could arise in part from effects on Akt
phosphorylation.
Phenotype of ae3−/− mice
ae3−/− mice have been reported to have no apparent
defects, and the results of our analysis of the cardiac
function of ae3−/− mice is comparable to these previous
studies [42,43,74]. Combined analysis of echocardio-
graphic measurements of ventricular wall dimensions,
chamber diameter and cardiac function between the two
genotypes further suggests that loss of AE3 does not
affect hypertrophy or cardiovascular performance. A sig-
nificant decrease in the HW/BW ratio in ae3−/− mice is
the result of a reduction in heart size, arising from a
decrease in cardiomyocyte size. This suggests a critical
role for AE3 in heart development.
Role of AE3 in control of cardiomyocyte pHi
Since cardiomyocyte steady-state pH was the same in
ae3−/− and WT mice, loss of Cl−/HCO3
− exchange activity
by ae3 deletion is likely compensated for by another pro-
tein. The principal Cl−/HCO3
− exchanger of cardiomyo-
cytes is SLC26a6 [23], making it the most likely acid
loading transporter to compensate for loss of AE3. Since
we did not see an increase in SLC26a6 expression,
SLC26a6 activation may occur through post-translational
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in ae3−/− mice. Since CAII increases the rate of CO2/
HCO3
− inter-conversion, it increases the rate of observed
Cl−/HCO3
− for SLC26a6 [75]. Thus increased CAII ex-
pression might in part compensate for loss of AE3. We
also noted a much larger increase in CAII message than
we saw for CAII protein. Since proteins carry out cellular
functions, not mRNA, we consider the protein change to
be a more reliable measure of cell response than the
mRNA increase. The reason for a muted increase in CAII
protein level in comparison to the mRNA rise remains
unclear.
The importance of AE3 in intracellular pH regulation
was, however, evident in the reduced rate of pHi recovery
from imposed intracellular alkalosis in cardiomyocytes
from ae3−/− mice compared to WT. Endothelin 1 stimula-
tion of myocardial Cl−/HCO3
− exchange activity in iso-
lated rat papillary muscle is almost totally attributable to
the AE3 isoform, on the basis of inhibition by an anti-AE3
antibody [61]. This provides a possible explanation for
the resistance of ae3−/− mice to pro-hypertrophic stimuli;
ae3−/− cardiomyocytes have reduced acidifying activity
to counter enhanced NHE1 activity associated with pro-
hypertrophic stimulation.Conclusions
We explored the role of AE3 in the development of car-
diomyocyte hypertrophy and cardiovascular pH regula-
tion, using AE3 deficient mice. Cardiomyocytes from
ae3−/− mice were protected from increases in cell sur-
face area, protein synthesis, and fetal gene reactivation
in response to hypertrophic stimulation. Steady-state
cardiomyocyte pHi in ae3
−/− mice was comparable to
WT, but slower to recover from imposed intracellular
alkalosis. Our findings demonstrate that AE3 is import-
ant in hypertrophic signaling pathways activated by PE
and ANGII, possibly acting through the hypertrophic
transport metabolon. Pharmacologically targeting AE3
activity in the event of hypertrophy is an attractive strat-
egy to treat heart failure patients.Additional files
Additional file 1: Figure S1. Effect of hypertrophic stimulation on
cardiomyocyte CAII protein expression. Cardiomyocytes isolated from
wildtype (ae3+/+) and knock-out (ae3−/−) mice hearts were cultured for
18 h and subjected to vehicle-alone (CON), angiotensin II (ANGII) and
phenylephrine (PE) treatment for further 24 h. Lysates prepared from
cardiomyocytes were probed for CAII expression by immunoblotting.
Immunoblots were stripped and probed for β-actin. A, Upper panel,
representative immunoblot of lysates probed with anti-CAII antibody;
lower panel, representative immunoblot stripped and re-probed with
anti-β-actin antibody. B, CAII expression normalized for β-actin expression
in cardiomyocytes treated with vehicle control (open bar), ANGII (black
bar) and PE (blue bar), expressed as a percentage of control.Cardiomyocytes isolated from ae3+/+ and ae3−/− mouse hearts, as
indicated. * P < 0.05, compared to control group (n = 4).
Additional file 2: Figure S2. Expression of NHE1 protein in WT and
ae3−/− mouse hearts. Cardiomyocytes isolated from adult mice hearts,
were lysed and probed on immunoblots for NHE1. A, Upper panel is a
representative immunoblot probed with anti-NHE1 antibody of
cardiomyocyte lysates prepared from wildtype (WT), ae3 heterozygote
(ae3+/−) and ae3 null (ae3−/−) mice; lower panel, representative
immunoblot stripped and reprobed with anti-β-actin antibody. B,
Summary of NHE1 amount quantified by densitometry and expressed as
a percentage relative to the WT group. *P < 0.05 compared to the WT
group (n = 4).
Additional file 3: Figure S3. Expression of Slc26a6 protein in WT and
ae3−/− mouse hearts. Cardiomyocytes isolated from adult mice hearts,
were lysed and probed on immunoblots for Slc26a6. A, Upper panel is a
representative immunoblot probed with anti-Slc26a6 antibody of
cardiomyocyte lysates prepared from wildtype (WT), ae3 heterozygote
(ae3+/−) and ae3 null (ae3−/−) mice; lower panel, representative
immunoblot stripped and reprobed with anti-β-actin antibody. B,
Summary of Slc26a6 amount quantified by densitometry and expressed
as a percentage relative to the WT group. *P < 0.05 compared to the WT
group (n = 4).
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